The earliest studies from Steve Rosenberg investigated the systemic administration of lymphokine-activated killer cells (patient lymphocytes cultured ex-vivo in the presence of IL-2 then re-infused) and IL-2 in patients with metastatic cancer. Here, IL2 is linked to metastatic malignant neoplasm.